Siblings are the greatest thing I have given my children. They are built-in friends who share the earliest memories, parents, and everything else. As my kids have gotten older, they have many “remember that time” stories they love to laugh about as they reminisce. Duchenne muscular dystrophy (DMD)…
While a Phase 3 clinical trial of Elevidys (delandistrogene moxeparvovec-rokl) has failed to meet its main goal, the results nonetheless showed that, compared with a placebo, the approved gene therapy led to notable improvements across numerous measures of physical function in boys with Duchenne muscular dystrophy (DMD). Top-line findings…
DYNE-251, an experimental treatment for Duchenne muscular dystrophy (DMD), is being well tolerated by patients in an ongoing clinical trial, according to the therapy’s developer, Dyne Therapeutics. Dyne also reported positive safety data from an ongoing trial of DYNE-101, the company’s investigational therapy for myotonic dystrophy type…
I’m looking out our patio doors at our backyard. I can hear the not-so-gentle Nebraska gales blowing around the wind chimes this morning as I watch leaves drift through the air. I’ve just come in from a fast-paced walk; sweat is sticking to my neck, and my heart rate is…
The U.S. Food and Drug Administration (FDA) has approved vamorolone for treating people with Duchenne muscular dystrophy (DMD), ages 2 and older. The therapy will be marketed as Agamree. “We strongly believe that this novel steroid has the transformational potential to make a significant difference for patients living with…
A gene editing approach can restore dystrophin production in cell and animal models of Duchenne muscular dystrophy (DMD), according to its researchers. The study, “Targeting Duchenne Muscular Dystrophy by Skipping DMD Exon 45 with Base Editors,” was published in Molecular Therapy Nucleic Acids. DMD is caused by…
I’ll admit that I was a support group cynic in my younger days. My attitude was that I’d figure things out on my own. I just couldn’t see the benefit of sitting around a table and talking to others about my struggle with facioscapulohumeral muscular dystrophy (FSHD). In retrospect,…
After three years of virtual academies, applications are now open for Duchenne Patient Academy 2023, an in-person training event for patient advocates for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The academy, presented by the World Duchenne Organization (WDO) and the Duchenne Data…
It’s no secret that I love the holidays. If you look through my past columns, you’ll find some about Christmas, Thanksgiving, and birthdays. I derive so much joy from creating a celebration for my family. Halloween is no exception. I am the queen of a good…
The U.S. Food and Drug Administration (FDA) has lifted its clinical hold on PGN-EDODM1, a medicine being developed by PepGen for myotonic dystrophy type 1, or DM1 — a subtype of the most common form of muscular dystrophy. With the hold lifted, PepGen is ready to…
Get regular updates to your inbox.